General discussion: Etiology and prevention of prostatic cancer.
Published in Cancer chemotherapy reports. Part 1
Initial chemotherapeutic trials in patients with inoperable or recurrent cancer of the prostate.
Published in Cancer chemotherapy reports. Part 1
This paper describes a random study being conducted to compare the value of 5-fluorouracil plus diethylstilbestrol vs diethylstilbestrol alone and the value of 5-fluorouracil vs CCNU in the treatment of stage D adenocarcinoma of the prostate. We have established that similar normal values of acid phosphatase are encountered in serum and bone marrow...
Fate of streptozotocin (NSC-85998)in patients with advanced cancer.
Published in Cancer chemotherapy reports. Part 1
We have investigated the distribution, biotranformation, and excretion of streptozotocin and its 14C- and 3H-labeled metabolities in 15 patients with advanced cancer. Streptozotocin was detected in the plasma during the first 3 hours after administration while radioactive products were present for longer than 24 hours. No unchanged streptozotocin w...
Combination chemotherapy with 5-fluorouracil (NSC-19893), methotrexate (NSC-740), and prednisolone (NSC-9900) (FAP proto...
Published in Cancer chemotherapy reports. Part 1
Review of selected experimental brain tumor models used in chemotherapy experiments.
Published in Cancer chemotherapy reports. Part 1
Single dose toxicity of actinomycin D (NSC-3053) in dogs.
Published in Cancer chemotherapy reports. Part 1
Urinary excretion of polyamines by patients with advanced malignancy.
Published in Cancer chemotherapy reports. Part 1
Levels of putrescrine, spermidine, and spermine in urine were determined by means of a sensitive ion-exchange chromatographic method in patients with advanced solid tumor malignancies, in patients with diseases other than cancer, and in normal control subjects. Elevation above 2 SDS of the normal mean were found in varying number of patients in eac...
Review of the current clinical status of platinum coordination complexes in cancer chemotherapy.
Published in Cancer chemotherapy reports. Part 1
During the past 3 years, eight hospitals and one cooperative study group have reported their initial clinical results with cis-dichlorodiammineplatinum (II). The most popular clinical schedule was 15-25 mg/m2/day for 5 days repeated every 3-4 weeks. Almost all patients had extremely advanced disease. Of 323 patients in whom response could be evalua...
Preclinical studies with triazinate (NSC-139105), an antifolate drug, in beagle dogs and rhesus monkeys.
Published in Cancer chemotherapy reports. Part 1
The effects of the intravenous administration of triazinate by single and multiple injections were studied in beagle dogs and rhesus monkeys. In dogs, dose levels ranging from 0.3125 to 40 mg/kg were given either as single doses daily for 5 days, or once weekly for 6 weeks. The 5-day regimen was also studied in monkeys with dose levels from 2.5 to ...
Preliminary pharmacokinetic model for adriamycin (NSC-123127).
Published in Cancer chemotherapy reports. Part 1
The systematic chemical control of cancer requires a quantitative knowledge of the pharmacologic disposition of antitumor drugs in both healthy and malignant tissues in the body. Pharmacokinetic models can predict the drug concentration in both tumor sites and healthy organs and hence may provide a predictive capability regarding both antitumor act...
